Lite Strategy (LITS) Retained Earnings (2011 - 2026)
Lite Strategy (LITS) posted quarterly Retained Earnings of -$462.3 million for Q1 2026, down 15.14% year-over-year from -$544.8 million in Q1 2025, and down 5.4% quarter-over-quarter from -$438.6 million in Q4 2025.
Lite Strategy (LITS) Retained Earnings (2011 - 2026) Analysis & Trends
Lite Strategy's Retained Earnings history runs 16 years deep, the most recent figure standing at -$462.3 million for Q1 2026.
- In Q1 2026, Retained Earnings fell 15.14% year-over-year to -$462.3 million; the TTM figure through Mar 2026 stood at -$462.3 million (down 15.14% YoY), while the FY2025 annual figure was -$404.2 million, down 4.11% from the prior year.
- Retained Earnings for Q1 2026 stood at -$462.3 million, down from -$438.6 million in the prior quarter.
- The five-year high for Retained Earnings was -$349.6 million in Q3 2023, with the low at -$462.3 million in Q1 2026.
- The 5-year median for Retained Earnings is -$396.0 million (2023), against an average of -$393.1 million.
- The sharpest annual moves came in 2022 and 2023: Retained Earnings decreased 17.03% in 2022, then increased 10.54% in 2023.
- Lite Strategy's Retained Earnings stood at -$380.5 million in 2022, then rose by 5.21% to -$360.7 million in 2023, then declined by 10.59% to -$398.9 million in 2024, then declined by 9.95% to -$438.6 million in 2025, then retreated by 5.4% to -$462.3 million in 2026.
- Business Quant data shows LITS's Retained Earnings at -$462.3 million in Q1 2026, -$438.6 million in Q4 2025, and -$407.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.65 Bn | 130.80 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.94 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.84 Bn | 59.66 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 57.38 Bn | 52.25 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 27.72 Bn | 9.33 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 4.38 Bn |
| 10 | Lite Strategy | 36.96 Mn | 29.42 Mn | - | -462.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -462.30 Mn |
| Dec 31, 2025 | -438.60 Mn |
| Sep 30, 2025 | -407.80 Mn |
| Jun 30, 2025 | -404.16 Mn |
| Mar 31, 2025 | -401.50 Mn |
| Dec 31, 2024 | -398.90 Mn |
| Sep 30, 2024 | -396.20 Mn |
| Jun 30, 2024 | -388.22 Mn |
| Mar 31, 2024 | -369.81 Mn |
| Dec 31, 2023 | -360.70 Mn |
| Sep 30, 2023 | -349.60 Mn |
| Jun 30, 2023 | -406.00 Mn |
| Mar 31, 2023 | -396.00 Mn |
| Dec 31, 2022 | -380.53 Mn |
| Sep 30, 2022 | -390.78 Mn |
| Jun 30, 2022 | -374.16 Mn |
| Mar 31, 2022 | -358.10 Mn |
| Dec 31, 2021 | -349.40 Mn |
| Sep 30, 2021 | -337.22 Mn |
| Jun 30, 2021 | -319.71 Mn |